Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

This publication has 25 references indexed in Scilit:

• Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial
  Journal of Clinical Oncology, 2003
• Cancer Statistics, 2003
  CA: A Cancer Journal for Clinicians, 2003
• Surrogate markers of response to cancer immunotherapy
  Expert Opinion on Biological Therapy, 2001
• SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
  Journal of Urology, 2000
• Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized study
  Cancer, 1996
• Major Histocompatibility Complex Class I and Class II Expression in Renal Cell Carcinoma and Modulation by Interferon Gamma
  Journal of Urology, 1996
• Expression and release of intercellular adhesion molecule-1 in renal-cancer patients
  International Journal of Cancer, 1995
• Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) on human renal cell carcinoma
  Clinical and Experimental Immunology, 1994
• The effect of α and γ interferon on cell growth and histocompatibility antigen expression by human renal carcinoma cells in vitro
  European Journal Of Cancer, 1993
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
  JNCI Journal of the National Cancer Institute, 1993